Ascendia

  MARKET NEWS

Vetter
FDA Revises Draft Guidance on Drug Delivery Device Performance Requirements
Neuralink's Blindsight Vision Implant Faces Questions Over Clinical Readiness and Human Trials
Fresenius Partners With WuXi Biologics to Add Up to 37 Biosimilar Candidates to Pipeline
Buccal Drug Delivery Market Set to Reach $6.48B by 2030
Yuyu Pharma Eyes Animal Health Market to Broaden Drug Development Opportunities
BioMarin Licenses Investigational Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
MilliporeSigma Opens $350 Million Bioprocessing Facility in South Korea
Frost & Sullivan Report Tracks China's Expanding Role in Global Biopharmaceutical Development
Biologics Contract Manufacturing Market Projected to Reach $110B by 2035
Lonza Expands Bioconjugation Capacity to Support ADC Manufacturing From Clinical Development to Commercial Supply
Adial Pharmaceuticals Rebrands as Azora Therapeutics Ahead of Planned Clinical Trial
FDA Proposes Streamlined Approval Pathway for Personalized Gene Therapies as CMS Expands Medicaid Access Initiative
Vertex Pharmaceuticals Plans New Research Facility at Harwell Science Campus
Codis Advances Haverhill Expansion to Increase Commercial Spray Drying Capacity
Humanitas Global Health Secures LSU AI Technology License to Advance Drug Discovery and Medication Safety
Adalvo Acquires Romiplostim Biosimilar Program to Expand Biologics Portfolio
ISR Market Research Develops AI-Powered Platform for Pharma Outsourcing Intelligence

  EXPERT CONTENT & RESOURCES

Aptar
Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

As injectable therapies evolve, so do the challenges of delivering them. Credence MedSystems has launched the Industry Education home on our website where we share practical perspectives on important topics in injectable drug delivery, including larger-volume prefilled syringes, precision intravitreal dosing, dual chamber delivery and other emerging drug delivery challenges.

The New Consumer Health Landscape: High Growth, High Expectations

The New Consumer Health Landscape: High Growth, High Expectations

Over the past few years, several major pharmaceutical companies have carved out or spun off their consumer healthcare (CHC) divisions, creating standalone organizations with the scale and scientific heritage of pharma but the commercial ambitions of fast-moving consumer brands. High-profile examples include Kenvue from Johnson & Johnson, Haleon from GSK and Opella from Sanofi, moves intended to unlock greater focus, agility and capital efficiency in businesses that operate under different market dynamics from prescription pharmaceuticals.

Monoclonal vs Polyclonal Antibody Production

Monoclonal vs Polyclonal Antibody Production

Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.

  FEATURED EDITORIAL

Upperton

  EXPERT INSIGHTS VIDEOS

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

  COMPANY PROFILE


Thermo Fisher Scientific Your trusted CDMO and CRO partner in drug development
Thermo Fisher Scientific is the world leader in serving science, empowering customers to make the world healthier, cleaner, and safer. We accelerate life sciences research, solve complex analytical challenges, enhance laboratory productivity, improve patient health, and develop life-changing therapies. Our global team delivers innovative technologies and pharmaceutical services through trusted brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
Thermo Fisher Scientific serves the pharmaceutical, biotechnology, and life sciences industries as a contract development and manufacturing organization (CDMO) and clinical services partner. Our end-to-end, integrated capabilities support every stage of drug development—from research and development and regulatory support to supply chain management and commercial manufacturing.
Learn More

  WHITEPAPERS & WEBINARS

H&T Presspart
WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 11 – Parenteral Contract Manufacturing
November 18 – Controlled Release
November 25 – Bioavailability
December 2 – Inhalation Drug Delivery

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com